Furthermore, in lung cancer harboring EGFR mutations, findings indicate that exosomes represent suitable biomarkers for research into cancer and clinical application while also revealing new pathways in the discipline of nanomedicine. This evidence concerns the gene EGFR and lung carcinoma.